MYC and neoplasm: At the level of specific genes and pathways, it is now well accepted that ERG interacts and modulates several tumor-relevant pathways involving AR, C-MYC, NKX3.1 and PTEN, all of which are more frequently identified to be altered in ERG fusion-positive prostate cancer, compared with ERG fusion-negative prostate cancer (27,28,33).